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Iron deficiency anemia (IDA) treatment is done to eliminate the causes of iron deficiency, iron supplementation, and rarely red blood 
cell transfusion. Divalent iron salts are the first line of oral treatment, but their use lead to frequent gastrointestinal adverse reactions. 
Iron is administered intravenously in the event of contraindications, intolerance, or inefficiency of oral therapy, but the parenteral route 
of drug delivery is not easily accepted by the patients. Intravenous preparations for single administration of a large dose of iron have a 
good therapy safety profile, but are more expensive than oral and are usually administered in a hospital setting. The availability of new 
iron compounds: sucrosomial iron, ferric citrate complexes, and ferric maltol widen the possibilities of IDA therapy and enable the better 
selection of iron preparations in various clinical situations. The innovative structure of sucrosomial iron leads to absorption in different 
ways (through endocytosis, the paracellular pathway, M cells of Peyer’s patches), ensures high bioavailability, and good tolerance of 
therapy. Ferric citrate, in addition to iron supplementation, reduces phosphate levels, and is beneficial to chronic kidney disease. Ferric 
maltol is currently being studied for IDA treatment with various comorbidities. Some studies indicate that new iron formulas may be 
used where intravenous intake has been recommended so far. So, we can expect treatment with iron nanoparticles and drugs that affect 
the intestinal microflora in the future. The paper presents current knowledge about new iron preparations that are already available in 
everyday practice, but also those that are at various stages of pre-clinical and clinical studies.
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Introduction
Iron deficiency anemia (IDA) is one of the most important common 
types of anemia worldwide, but its prevalence varies with latitude, 
country socioeconomic conditions, and patient age. It is estimated that 
IDA affects 1.24 billion people worldwide, most often children under 
the age of 5 and women of childbearing age. Globally, approximately 
90% anemia cases in young children are caused by iron deficiency 
and infections. Deficiency anemia, including IDA and anemia in chronic 
kidney disease (CKD), are the two most common types of anemia in 
the elderly in the world [1]. It is estimated that in developed countries, 
IDA accounts for approximately 12–25% of anemia cases in patients 
over 60 years of age, who are not hospitalized [2–5].
The etiology of iron deficiency anemia varies among age groups. 
Increased need of iron requirements and dietary deficiencies are the 
most common causes of IDA during pregnancy, breastfeeding, and 
childhood. Blood loss during menstruation is the leading cause of iron 
deficiency in menstruating women, and iron malabsorption can occur 
at any age for a variety of reasons. One of the most common causes 
of iron deficiency, especially in the elderly, is bleeding, particularly from 
the gastrointestinal tract. Pharmacotherapy which commonly uses non-
steroidal anti-inflammatory drugs, anticoagulants, antiplatelet drugs, or 
proton pump inhibitors thereby increasing the risk of IDA. The etiology of 
iron deficiency also includes blood loss caused by medical procedures 
and surgery, especially in the elderly. Iron deficiency may appear in 
the course of many diseases, e.g., inflammatory bowel disease, 
chronic circulatory failure, chronic kidney disease, cancer, rheumatoid 
arthritis, and obesity. A rare, genetically determined form of IDA is iron-
refractory iron deficiency anemia (IRIDA) [6–10]. Hepcidin, which is 
a direct inhibitor of ferroportin, plays a central role in the pathogenesis 
of iron metabolism disorders. Up-regulation of hepcidin inhibits iron 
transport from enterocytes and macrophages result in decreased 
iron availability for erythropoiesis. Hepcidin expression is inhibited by 
iron deficiency, erythoferron, and hypoxia. Contrarily, increased iron 
intake and inflammatory response increase the expression of hepcidin. 
Both the deficiency and resistance to erythropoietin contribute to the 
pathogenesis of anemia. A detailed discussion of the pathogenesis of 
IDA is beyond the scope of this article and can be found in previously 
published papers [9, 10, 11].
Diagnostics
Coexistence of iron deficiency and inflammatory response give rise 
to some difficulties in the diagnosis and treatment of IDA. Therefore, 
practically absolute iron deficiency (ID) and functional iron deficiency 
(FID) is determined for diagnosis. ID indicates a reduction in total iron 
stores in the body and the need for iron supplementation. In most 
patients, ID is recognized at serum ferritin levels <30 ng/mL. The same 
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ferritin levels define iron deficiency anemia, with concentrations 
typically below 10–12 ng/mL [6]. There are no common criteria for 
identifying IDA in the literature. According to a review published in 2020 
in the European Journal of Hematology, ferritin concentrations 
<12–50 ng/mL and transferrin saturation (TSAT) <16% were given 
as diagnostic criteria for IDA [7]. In turn, the publication of the 
American Society of Hematology in December 2019 proposed 
to diagnose IDA with ferritin <20 ng/mL and TSAT <20% [10]. For 
some diseases, the need for iron treatment is defined differently. 
In cancer, ID is diagnosed at a ferritin concentration of <100 ng/mL 
[12] while in chronic kidney disease, iron supplementation is 
recommended at  ferritin level ≤500 ng/mL and TSAT ≤30% [13]. 
However, intravenous iron therapy can be used in symptomatic 
heart failure when ferritin is <100 ng/mL or <300 ng/mL and 
TSAT <20% [14, 15].
FID is a state of unavailability of sufficient iron for erythropoiesis 
despite adequate reserves in the body and occurs in anemia of 
chronic disease (ACD) or in the course of IRIDA [10]. FID in the 
course of IRIDA is diagnosed when serum iron concentration is 
decreased and TSAT <10%, but at different ferritin concentrations 
[7]. ACD with iron deficiency is diagnosed in patients with increased 
levels of inflammatory response markers and TSAT <20%, while 
serum ferritin concentrations are 30–100 ng/mL [16,17] or at 
20–100 ng/mL according to some authors. [10]. The diagnosis of 
ACD is confirmed by the concentration of ferritin >100 ng/mL and 
TSAT <20% [7, 10, 18]. Serum soluble transferrin receptor (sTfR) 
concentration, sTfR to log ferritin concentration ratio (sTfR/log sF), 
and serum hepcidin concentration may be helpful in differential 
diagnosis of ID and ACD. In the course of ACD, sTfR is normal, 
hepcidin concentration is increased, and sTfR/log sF is below <1 
[18, 19, 20]. During iron deficiency in the course of ACD, sTfR/log sF 
is >2, while the concentration of hepcidin varies [18, 20]. Currently 
hepcidin concentration is not used in routine practice mostly due to 
the lack of standardized reference values. But, hepcidin concentration 
may become one of the important parameters in the diagnosis and 
treatment of iron disorders in the future. In IDA, hepcidin levels might 
play an important role in deciding on the route of iron supplementation: 
low levels indicate the possibility of oral supplementation, and high 
levels indicate the need for parenteral treatment.
Treatment of IDA
In IDA, it is important to diagnose and eliminate the cause of iron 
deficiency while simultaneously maintaining dietary management 
and iron supplementation. The first line of treatment in patients 
without contraindications is oral supplementation with divalent 
iron – especially iron sulfate (i.e., salts of divalent iron (Fe2+)). The 
second line of treatment includes trivalent iron (Fe3+) preparations, 
e.g., complexed with sugars or protein succinate [21]. Preparations 
containing divalent iron, e.g., iron sulfate and gluconate or iron 
fumarate are characterized by better bioavailability compared to 
trivalent iron preparations. Drugs containing divalent iron salts are 
relatively cheap, but should not be taken during meals as their use is 
associated with frequent gastrointestinal tract side effects [22]. Up to 
70% of patients treated with oral iron preparations report symptoms 
such as: abdominal pain, nausea, and constipation, that often 
lead to discontinuation of the treatment [23]. Gastrointestinal side 
effects result from the instability of bivalent iron, which is converted 
into trivalent iron by oxidation process resulting in the formation of 
reactive oxygen species (ROS). ROS not only damage enterocytes 
but also induce systemic inflammation and tissue damage. Moreover, 
only 10–20% of iron in the digestive tract is absorbed, and most of 
it remains available to intestinal microorganisms, which in turn alters 
the intestinal microflora and can result in intestinal inflammation and 
possibly neoplastic transformation [24, 25]. Due to lower absorption, 
the use of oral preparations of trivalent iron is recommended in 
the second-line of treatment in patients with intolerance to bivalent 
iron preparations. Parenteral iron supply is reserved for the cases 
having significant intolerance to oral preparations, exacerbation of 
inflammatory bowel disease (IBD), significant iron loss, the need 
to quickly restore iron stores, impaired iron absorption, active 
inflammation, iron deficiency in the course of chronic kidney disease 
especially when treated with erythropoietin, and in patients on 
dialysis. Preparations for parenteral administration with trivalent iron 
may contain iron sucrose complex, sodium-iron gluconate complex, 
iron dextran, as well as iron, sorbitol and citrate complex. The use of 
parenteral iron preparations, especially iron dextran, is associated 
with some risk of hypersensitivity reactions, including severe cases 
[26]. Intravenous iron supply causes faster and more effective 
restoration of iron resources in the body and also under conditions of 
inflammation, but involves a risk of iron overload. For several years, 
parenteral iron preparations for a single administration of a large 
dose of iron have been available in the form of: iron III hydroxide 
and carboxymaltose complex (Ferinject) [27] and iron isomaltoside 
1000 III (Monover) [28]. It is already proved that their effectiveness 
is very good and has low risk for side effects, but they are expensive 
and are not used in outpatient care in Poland.
Red blood cell (RBC) transfusion is only used in patients with 
severe anemia and hemodynamic instability, signs of organ 
hypoxia (especially coronary symptoms), and active bleeding. RBC 
transfusion is associated with a number of well-documented serious 
immune and non-immunological adverse events mentioned above 
[29].
So, it may be concluded that though there are many oral iron 
preparations available at present, their use may be limited due to 
side effects, intolerance, or contraindications. On the other hand, 
intravenous iron preparations are not preferred by patients as they 
are more expensive and usually require hospitalization. Therefore, 
the aim of this study is to discuss new, original preparations for 
oral iron supplementation: sucrosomial iron, iron citrate complexes, 




Currently, a new preparation of sucrosomial iron, which is 
a patented one, is available, i.e., Sideral RM (SRM, PharmaNutra 
Spa), in which iron pyrophosphate (Fe3+) is protected by a double 
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Table I. Efficacy and safety of novel iron agents in a different clinical setting





Study type and 
duration Dosage of agents Results SAEs AEs
Sucrosomial Iron 
Pisani et al. [38]
NDD-CKD 
 n = 99
RCT  
3 months
SI 30 mg/d p.o. vs. 
FG IV (125 mg/week; 
1000 mg total dose)
Increses Hb evels, ferritin 
in both groups; but stable 
after discontinuation in FG 
group
No in both 
group
Fever AES in SI 
than FG group4
Sucrosomial Iron
Mafodda et al. [39]
Solid tumor  
 n = 64
RCT pilot  
2 months
SI (30 mg/d) vs.  
FG IV (125 mg/week) 
plus darbepoetin in 
both groups
No difference in the Hb 









Abbati et al.  [40]
Inflammatory 
bowel disease 
 n = 30
Prospective  
3 months
SI (30 mg/d) Iron parameters, serum 
hepcidin improved 
significantly, Hb increased 







Elli et al.  [41]
Celiac disease 
 n = 43
Prospective  
3 months
SI (30 mg/d) vs. FS 
(105 mg EI/d)
Increase Hb levels 
compared to baseline 
(+10.1% and +16.2% for 
sucrosomial and sulfate 
groups, respectively)
















SI (30 mg/d) plus 
darbopoietin
Increase of Hb of 1.73 g/dL 
during 8 weeks, 8 patients 
required RBC transfusion










SI (28 mg/d) vs. IRS 
(300 mg IV)
No differences in ferritin, 
TSaT, Hb, before and after 
treatment with SI
No in both 
group
No in both  
group
Ferric citrate 
Block et al. [48]




FC (n = 117) vs.  
placebo (n = 115)
Increases Hb, repletes iron 
stores, reduces levels of 
serum phosphate, urinary 
phosphate excretion, and 
FGF-23





severity of AEs 
similar between 
FC vs. placebo 
groups6
Ferric citrate 
Fishbane et al. [49]
NDD-CKD  
 n = 99
RCT phase 3 
16 weeks
FC (starting dose 3 
x 210 mg EI/d) vs. 
placebo
52.1% of FC group vs. 19.1% 
placebo increase in  






75.3% of FC 




Chertof et al. [58]
NDD-CKD  
n = 385
Two RCT phase 
2 (12 weeks) 
and phase 3  
(16 weeks)
FC (starting dose 3 
x 210 mg EI/d) vs. 
placebo
Correction of IDA  











AEs8 higher rates 
than in placebo 
group
Ferric maltol 
Gasche et al. [63]
Inflammatory 





FM (60 mg/d) vs. 
placebo
Improvements in Hb in FM 
group, normalization of Hb 




58% in FM 
group vs. 72% in 
placebo group9
Ferric maltol 




RCT (first 12 
weeks) open-
label ferric 
maltol for 52 
weeks
FM (30 mg/d) vs. 
placebo
Normalization of Hb in ≥80% 






24% patients of 
FM group10
AEs  – adverse events; CKD - chronic kidney disease; d – day; EI- elementar iron; FG - ferrous gluconate; Hb- hemoglobin; FS - ferrous sulfate; FM – ferric maltol; IRS –  iron sucrose; 
NDD –  nondialysis-dependent;  RCT – randomized controlled trial; SAEs – serious adverse events; SI – sucrosomial iron; tabl – tablets; TSAT – transferrin saturation; UC–ulcerative colitis; 
VI – intravenous injection; 1 – Hb from 9.4 to 12.7 g/dL in SI group and from 9.2 to 12.9 g/dL in FG; 2 – Hb from 11.67 to 12.37 g/dl; 3 – SAEs in FC group: atrial fibrillation, gut complications, 
procedural complications, hypoglycemia; 4 – SAEs in SRI group: constipation 5%, diarrhea 5%, in FG group: headache 18%, hypotension 12%, infusion site reaction 12%;  5 – gastrointestinal 
adverse events: 30% of patients, other AEs (the most common: headache, sore throat, infection) 50% of patients; 6 – Most common AEs: diarrhea 20.5% vs. 16.4% and constipation 18.8% 
vs. 12.9% respectively; 7 – gastrointestinal AEs were the most frequent 49.5% FM vs. 27.7% placebo group; 8 – gastrointestinal AEs: diarrhea, constipation, nausea discolored feces; 9 – 
mainly gastrointestinal AEs FM vs. placebo: abdominal pain (13.3% vs. 11.7%, respectively), diarrhea (8.3% vs. 10.0%) and constipation (8.3% vs. 1.7%), naso-pharyngitis in  6.7% of FM 
vs. 11.7% of placebo group, 10 – AEs: abdominal pain 7% patients, constipation 5%, flatulence 5% and diarrhea 3%, 11 – SAEs: severe abdominal pain, worsened ulcerative colitis, herpes 
zoster, peritonitis, hernia, cholesteatoma removal, rectal haemorrhage  
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layer of phospholipids and a sucrosomial shell called sucrester. 
The phospholipid layer is produced mainly from sunflower lecithin, 
while sucrester is a surfactant resulting from the esterification of fatty 
acids with sucrose. Other ingredients, such as tricalcium phosphate 
and starch, stabilize the molecule [30, 31]. The innovative formula 
allows iron absorption through various routes in the small intestine. 
A significant part of SRM is absorbed through endocytosis of the 
microcapsule by enterocytes of the intestinal epithelium. Further, 
absorption in part occurs by paracellular transport, and partly by 
specialized microfold cells of Peyer’s patches (M cells) [31, 32, 33]. 
The results obtained in in vitro studies and animal models indicate 
that iron in the SRM formula is protected against reduction to 
divalent iron on the enterocyte surface and absorption is probably 
independent of divalent metal transporter 1 (DMT1) [30]. The specific 
route of absorption by M cells, a characteristic for sucrosomial iron, 
initially causes the iron to enter the lymphatic system instead of 
entering the blood. Different absorption routes and partial bypassing 
of the portal system and the liver is probably responsible for the high 
bioavailability of this preparation. Sucrester forms a protective layer 
that prevents iron from being released in the stomach, and allows 
release in the small intestine. In addition, iron is reduced to divalent 
ions on the surface of enterocytes only to a small extent, the amount 
of unabsorbed iron on the intestinal epithelium is reduced, and there 
are fewer gastrointestinal tract side effects [31, 32].
A number of in vitro and in vivo tests performed in healthy laboratory 
animals indicate better bioavailability of sucrosomial iron compared 
to other iron formulas, also other preparations of iron pyrophosphate 
or iron sulfate [30, 31, 34]. In vivo studies performed in animals with 
anemia, a greater improvement was observed in iron metabolism 
parameters and Hb metabolism with the use of SRM versus iron 
sulfate or iron dextran [35, 36]. Additionally, when mice with IDA 
treated with SRM, no increase in inflammatory parameters or 
a significant increase in hepcidin transcription was shown. Iron sulfate 
used in this study at the same doses caused a significant increase in 
hepcidin mRNA in hepatocytes and in serum hepcidin concentration. 
Iron sulfate induced the expression of various inflammatory markers 
[suppressor of cytokine signaling 3 (Socs3), serum amyloid A 1 
(Saa1), interleukin-6 (IL6), and C-reactive protein (CRP)], which was 
not observed with SRM [35].
The safety and good tolerance of sucrosomial iron have been 
confirmed in patients with various diseases, including CKD [37, 38], 
tumors [39], inflammatory bowel diseases [40], and celiac disease 
[41]. The recommended daily dose for the treatment of IDA used 
in most studies is 30 mg/day of sucrosomial iron. The use of SRM 
together with darbepoetin alfa gives a similar increase in Hb in cancer 
patients with anemia associated with chemotherapy, with the use of 
intravenous preparations having better tolerance and without the risk 
of side effects typical of parenteral iron therapy [39]. Other studies on 
the use of SRM in oncohematology include a retrospective analysis 
of therapy cost in refractory anemia [42] and the effectiveness of 
anemia treatment in the course of lymphoproliferative diseases [43]. 
In patients after bariatric surgery, it was concluded that SRM can 
replace the intravenous iron supply [44]. Campanella and coauthors 
had similar observations for IDA patients, as SRM was shown to be 
effective and well-tolerated in situations where parenteral therapy 
was indicated [45]. Some authors indicate the economic benefits of 
sucrosomial iron, especially when compared to parenteral therapy 
[42, 46]. However, most studies have been carried out in small groups 
of patients (20–90) and there have been only a few high-quality 
studies, so further studies are needed to completely evaluate the 
effects of SRM in different disease entities. Recruitment is currently 
underway for clinical trials involving sucrosomial iron in patients with 
anemia prior to cardiac surgery (ClinicalTrials.gov: NCT03560687), 
undergoing knee or hip orthopedic surgery (ClinicalTrials.gov: 
NCT04078880), and in patients with heart failure – including an 
efficacy comparison of various oral and intravenous iron preparations 
(ClinicalTrials.gov: NCT03833336). The use of SRM in heart failure 
would be an attractive alternative to intravenous treatment in patients 
who do not require hospitalization.
Iron citrate
Iron citrate was originally used as a non-calcium formulation to reduce 
the phosphate pool in patients with CKD. During treatment, it was 
observed that it has the ability to improve Hb parameters in patients 
with anemia [47]. In a double-blind, placebo-controlled, randomized 
study of patients with IDA and CKD stages 3–5, iron citrate has been 
found to improve iron metabolism parameters, increase Hb levels, 
reduce serum phosphate levels, and decrease fibroblast growth 
factor 23 (FGF23) levels over 12 weeks of treatment [48]. Fishbane 
et al. [49] demonstrated the efficacy, safety, and good tolerability of 
iron citrate treatment in non-dialyzed patients. Iron citrate can be 
used in non-dialyzed patients with CKD and IDA based on current 
recommendations, but further studies are needed to determine the 
role of iron citrate in dialyzed patients [50]. Iron citrate has also been 
studied in patients with CKD and heart failure (HF). Based on the 
results of phase 2 and 3 studies, it is found that HF did not affect the 
improvement in Hb, iron, or phosphate, but patients with HF reported 
more side effects [51]. The role of iron citrate in patients with CKD 
and HF requires further research.
Auryxia (Keryx Biopharmaceuticals, Inc.) is one of the oral iron citrate 
formulations approved for the treatment of hyperphosphatemia and 
IDA in CKD. Auryxia is distinguished by the fact that it is a solid mixture 
of iron citrate coordination complexes (FCCC) with a defined molar 
ratio of iron (Fe3+) to citrate anions. X-ray crystallography reveals that 
these complexes are mono-, di-, tri- and nanonuclears with 2–9 iron 
atoms present in the complex, predominantly with dinuclears. The 
presence of various complexes increases the solubility and availability 
of iron under various pH conditions. Oligomeric complexes dominate 
under low pH conditions, while monomeric complexes at high pH 
[50, 52]. It is believed that the ability to form oligomeric complexes at 
low pH, i.e., in the stomach, contributes to the formation of insoluble 
complexes with phosphate ions and thus enables capture and 
removal of dietary phosphate from the body. The structure of iron-
citrate complexes prevents the hydrolysis of ferric ions, which could 
lead to the formation of insoluble compounds. In addition, the iron 
in this preparation is weakly oxidized leading to the reduction in the 
formation of free oxygen radicals and lowers the risk of damage to 
the cells of the gastrointestinal mucosa. This reduces the likelihood 
of side effects [53]. The absorption of iron from Auryxia is mainly via 
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the known enterocytic absorption pathway. It is believed that other 
possible iron citrate absorption pathways include an extracellular 
pathway [54] and the mechanisms involving intestinal microflora 
[55]. Iron citrate complexes have been shown to capture and reduce 
phosphate and FGF23 levels in both dialyzed and non-dialyzed CKD 
patients [53]. As phosphates [56] and FGF23 [57] are independent 
factors of cardiovascular complications in patients with CKD, this 
preparation might be particularly beneficial in patients with CKD 
anemia. However, more research is needed to investigate whether 
the reduction of these parameters by Auryxia actually translates into 
cardiovascular risk reduction. Similarly to other iron preparations, 
gastrointestinal symptoms were the main adverse reactions in the 
analysis of two randomized phase 2 and 3 clinical trials of Auryxia 
in non-dialyzed patients with CKD. Serious adverse events that 
occurred in 20 patients treated with Auryxia compared to the group 
of 21 placebo patients include: cardiovascular disorders (3.7% vs. 
2.7%) and infectious complications (2.6% vs. 3.7%) [58]. Phase 4 
clinical trials are currently underway in adult, non-dialyzed CKD 
patients with IDA (ClinicalTrials.gov: NCT03236246). There were 
some alarming reports on increased level of amphiregulin in mice 
when treated with iron citrate. It suggests that there is a potential risk 
of intestinal carcinogenesis. Such an effect was not observed for iron 
sulfate [59].
Ferric pyrophosphate citrate (FPC) is an intravenous formulation 
marketed under the trade name Triferic (Rockwell Medical Inc.) 
approved for iron supplementation in adult dialyzed patients with 
CKD [60]. FPC is highly water-soluble, non-colloidal preparation 
containing trivalent iron (1 molecule of iron pyrophosphate and 
2 molecules of iron citrate). The preparation was well tolerated and 
serious adverse events occurred at a similar frequency as in the 
placebo group, the most common being gastrointestinal side effects. 
A significant reduction in the requirement for therapy with erythropoiesis 
stimulating agents was also reported [60]. Further studies in dialyzed 
patients are ongoing (ClinicalTrials.gov: NCT04042324).
Iron maltol
Feracrru in Europe or Accrufer in the United States (ferric maltol; 
Shield Therapeutics plc) is a new oral iron formula that consists of 
a stable trivalent iron complex bound with three maltol ligands. It is 
believed that the ratio of maltol to iron in this formula prevents the 
formation of iron hydroxide polymers and promotes iron absorption at 
a neutral pH of the gastrointestinal tract [61]. Iron trimaltol possesses 
both hydrophilic and lipophilic properties, and after oral administration, 
iron reaches the intestinal mucosa in a complexed form, which may 
allow for more effective uptake of elemental iron by enterocytes, 
especially when compared to iron salts. The complex does not pass 
through the intestinal mucosa. It is broken down into iron and maltol 
and both are absorbed separately [62]. Based on the summary of 
medicinal product characteristics, it is concluded that Feracrru should 
not be used in patients with exacerbation of inflammatory bowel 
disease or inflammatory bowel disease with hemoglobin <9.5 g/dL. 
In addition, it was shown that excessive use of the preparation may 
cause toxic effects, especially in children. The manufacturer warned 
that Feraccru must not be given to children. But, a randomized, 
double-blind, placebo-controlled trial in more than 300 patients 
with ulcerative colitis or Crohn’s disease and IDA demonstrated 
comparable safety of iron maltol to placebo with no exacerbations 
of IBD [63]. There was also a significant improvement in Hb levels, 
and 2/3 of patients shown normalization of Hb levels after 12 weeks 
of administration of 30 mg of iron maltol twice a day [63]. In another 
phase 3 study of iron maltol in IDA in the course of inflammatory 
bowel disease, the effectiveness and normalization of Hb parameters 
was demonstrated in 80% of patients during 20–64 weeks of therapy, 
with good tolerability and safety profile [64]. Iron maltol is of great 
interest to researchers. The recruitment for Phase 1 trial of iron 
maltol in children and adults with IDA (in various doses) has been 
completed just now (ClinicalTrials.gov: NCT03181451). Currently, 
several interventional clinical trials with iron maltol are in recruitment 
phase, i.e., for patients with IDA and heart failure (ClinicalTrials.gov: 
NCT03774615), IDA and pulmonary hypertension (ClinicalTrials.
gov: NCT03371173), with CKD (ClinicalTrials.gov: NCT02968368), 
with IBD compared to an intravenous formulation (ClinicalTrials.
gov: NCT02680756), and in hospital practice (ClinicalTrials.gov: 
NCT03247816).
Other drugs for IDA therapy
Research is underway on nanomaterials delivering iron to cells to 
improve the bioavailability and, at the same time, the tolerance of 
oral treatment [65–68]. The studies include biocompatible iron 
nanoparticles (Fe3O4) with the addition of vitamin C [68]. Studies of 
Fe and Fe/Zn nanocompounds produced by scalable flame aerosol 
technology are conducted in rats. So far, it has been shown that 
these nanocompounds are characterized by high bioavailability 
(comparable to iron sulfate) and do not cause stool discoloration 
[65]. One of the most promising nanomaterials used in animal 
models is iron hydroxide adipate tartrate (IHAT) [67]. The results of 
a controlled, double-blind, three-arm trial of IHAT in children with IDA 
aged 6–35 months in Gambia has shown that iron deficiency was 
eliminated and Hb was improved without inducing gastrointestinal 
side effects. In addition, a beneficial effect on the intestinal microflora 
was observed, including the reduction of pathogenic intestinal flora. 
IHAT has shown effectiveness similar to iron sulfate in terms of IDA 
treatment effects with a lower risk of diarrhea [69]. In the future, 
more research is expected on the effects of the microbiome on iron 
management and the treatment of anemia. Existing studies indicate 
the role of iron in the composition of the intestinal microflora, and this, 
in turn, may translate into the formation of intestinal inflammation or 
carcinogenesis.
Conclusions
The emergence of new oral iron preparations has widely expanded 
the possibilities of iron supplementation in IDA, especially in the 
presence of concomitant diseases such as CKD, HF, inflammatory 
bowel diseases, or cancer. Some studies indicate that sucrosomial 
iron and iron citrate complexes can replace intravenous iron under 
certain conditions. Sucrosomial iron is highly bioavailable and well 
tolerated due to its innovative structure and absorption via various 
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routes. Iron citrate complexes, in addition to good absorption in 
various pH conditions, lower phosphate concentration, which is 
beneficial for patients with CKD. Iron maltol is currently being studied 
in IDA patients with various comorbidities. New nanomaterials are 
being developed to deliver iron innovatively to cells. However, all 
these substances require further studies in larger patient populations 
to assess the actual effectiveness and safety of the therapy.
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